Mechanisms of Uptake and Interaction of Platinum Based Drugs in Eukaryotic Cells

Nejdl, Lukáš; Kudr, Jiří; Blažková, Iva; Chudobová, Dagmar; Skaličková, Sylvie; Ruttkay-Nedecký, Branislav; Adam, Vojtěch; Kizek, René

doi:10.1007/978-3-662-44559-4_25

Cited by 7 publications

(7 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ECT enhanced the permeability of cisplatin into the tumor cell and potentiated the effect the effect of cisplatin on metastatic lesions of tumours by endocytic-like mechanism. The added advantage of electrochemotherapy with intra-lesional cisplatin is that the main adverse effects of cisplatin like renal toxicity, gastrointestinal toxicity, peripheral neuropathy, myelotoxicity, asthenia, ototoxicity and also resistance to cisplatin (Nejdl et al, 2014) can be prevented by the ECT procedure as it does not involve systemic administration of the drug.…”

Section: Resultsmentioning

confidence: 99%

Electrochemotherapy with intra-tumoral cisplatin for the treatment of fibrosarcoma in a horse

Bharathidasan

William

George

et al. 2018

IJAR

View full text Add to dashboard Cite

A two years old Kathiawar stallion was reported with the history of two, pedunculated hard mass medially on the thigh and hock of the right hind limb, progressively increasing for the past two months. Fine needle aspiration cytology revealed fibrosarcoma.The tumour on the medial aspect of the thigh was injected with cisplatin intra-tumorally at a dose rate of 0.3 mg/cm 3 of tumour volume and was exposed to ECT. The tumour on the medial aspect of the hock was excised incompletely to preserve skin and subcutaneous tissues around the tumour for wound opposition and treated with intra-tumoral injection of cisplatin followed by ECT. Following electrochemotherapy complete response was noticed onthe 3 rd and 4 th week for the tumours on the thigh and hock respectively. No recurrence was noticed during the follow-up period of one year revealing ETC with cisplatin as a single treatment and also in combination with surgery is effective for the treatment of fibrosarcoma in equines.

show abstract

Section: Resultsmentioning

confidence: 99%

Electrochemotherapy with intra-tumoral cisplatin for the treatment of fibrosarcoma in a horse

Bharathidasan

William

George

et al. 2018

IJAR

View full text Add to dashboard Cite

show abstract

“…A2780CP and A2780S ovarian cancer cell lines are resistance and sensitive to cisplatin, respectively [16]. Since the cytotoxicity of carboplatin is directly associated with the amount of drug that enters the cell [17], this phenomenon can be related to the differences in the cell entry mechanism of carboplatin and carboplatin loaded liposomal nanoparticles over the anticancer drug cisplatin. Further research is recommended to obtain more details of this phenomenon.…”

Section: Discussionmentioning

confidence: 99%

Preparation, Characterization and Cytotoxic Effects of Pegylated Nanoliposomal Containing Carboplatin on Ovarian Cancer Cell Lines

et al. 2016

View full text Add to dashboard Cite

Carboplatin is a chemotherapeutic agent used against various malignancies such as ovarian carcinoma. The aim of this study is to improve the therapeutic efficacy of carboplatin using pegylated liposomal nanocarriers. Nanoparticles were synthesized using thin film hydration technique and characterized for shape morphology, particle size, zeta potential and drug-release properties. In the next step, A2780S and A2780CP ovarian cancer cell lines were used to determine the efficacy of nanodrug by MTT assay. The particle size and zeta potential of nanodrug were measured 244.3 ± 19.6 nm and -22.9 ± 1.7 mV, respectively. High encapsulation capacity (78.6 ± 3.7 %) confirmed the efficiency of technique. The cytotoxicity results also showed that nanodrug compared to free drug improve the efficacy of carboplatin against both A2780S ( < 0.01) and A2780CP ( < 0.05) cell lines. In conclusion, the findings of our study suggested pegylated liposomal nanocarriers are proper for carboplatin delivery to ovarian cancer cell lines A2780S and A2780CP.

show abstract

“…The formation of these covalent adducts with DNA causes the inhibition of transcription and replication, eventually leading to cell death. 8 Consequently, further platinum complexes have been developed with distinctly different mechanisms of action as a way to address the limitations of clinically used platinum(II) drugs. This includes platinum(II) complexes that incorporate a broader range of ligands such as heteroaromatic, iminoether, or asymmetric aliphatic amine ligands that allow them to form monofunctional adducts or bind noncovalently to biological target(s).…”

Section: ■ Introductionmentioning

confidence: 99%

Novel Platinum(II) and Platinum(IV) Antitumor Agents that Exhibit Potent Cytotoxicity and Selectivity

et al. 2022

View full text Add to dashboard Cite

A novel platinum(II) complex 47OMESS(II) and its platinum(IV) derivative 47OMESS(IV) were synthesized and characterized. Cytotoxicity studies against mesenchymal cells (MCs) and lung (A549), breast (MDA-MB-231), and melanoma (A375) cancer cells demonstrated 7−20-fold superior activity for both complexes relative to cisplatin. Remarkably, 47OMESS(IV) demonstrated 17−22-fold greater selectivity toward the cancerous cells compared to the non-cancerous MCs. Western blot analysis on A549 cells showed the involvement of the intrinsic apoptotic pathway. Cellular fractionation and uptake experiments in A549 cells using ICPmass spectrometry (MS) indicated that 47OMESS(II) and 47OMESS(IV) cross the cellular membrane predominantly via active transport mechanisms. The significant improvement in selectivity that is exhibited by 47OMESS(IV) is reported for the first time for this class of complexes.

show abstract

Mechanisms of Uptake and Interaction of Platinum Based Drugs in Eukaryotic Cells

Cited by 7 publications

References 95 publications

Electrochemotherapy with intra-tumoral cisplatin for the treatment of fibrosarcoma in a horse

Electrochemotherapy with intra-tumoral cisplatin for the treatment of fibrosarcoma in a horse

Preparation, Characterization and Cytotoxic Effects of Pegylated Nanoliposomal Containing Carboplatin on Ovarian Cancer Cell Lines

Novel Platinum(II) and Platinum(IV) Antitumor Agents that Exhibit Potent Cytotoxicity and Selectivity

Contact Info

Product

Resources

About